A new study in JAMA Pediatrics finds that sex and money each play a role in U.S. parents' reluctance to vaccinate their children against the human papillomavirus. But a lack of easy-to-understand information about the shots--and often, the lack of a doctor's clear recommendation for them--are also helping to depress vaccination rates.
While half of U.S. teenage girls receive one dose of human papillomavirus vaccine, far fewer come back to complete the regimen. What is less clear is whether one dose offers any protection, but a new study offers some hope.
A competitor is threatening to chip away at sales of Merck's human papillomavirus vaccine Gardasil. Fortunately for Merck, it is the company developing the rival.
Merck believes it can win near-term approval for a new HPV vaccine that will do better than Gardasil in guarding women against the virus that causes cervical cancer. But the vaccine's estimated peak sales potential won't relieve the company's migraine over weakening drug sales.
Merck once again reached for the ax this week, outlining plans to lay off 8,500 staff in a bid to save $2.5 billion a year. The reorganized company will focus R&D dollars on four areas, one of which is the vaccines business.
In mouse models, Advaxis' immunotherapy LmLLO in combination with an anti-PD-1 antibody significantly improved immune and therapeutic efficacy in preclinical mouse models of HPV-associated cancers.
Israeli health ministry officials are reportedly considering dropping plans to give HPV vaccines to 52,000 teenage girls.
After struggling to persuade parents to vaccinate teenage girls against human papillomavirus, health experts expected a frosty reception when labeling was expanded to include boys. Yet early data shows Merck's Gardasil is off to a good start.
Nonprofit PATH has come under attack this week after a parliamentary committee accused it of subterfuge in a human papillomavirus vaccine project that gave GlaxoSmithKline's Cervarix and Merck's Gardasil to girls in two Indian states.
A malaria shot designed by vaccine maker Inovio Pharmaceuticals killed the disease in infected cells in animals while boosting immune responses, according to a new study.